CELLDEX THERAPEUTICS, INC. 13,377,926 Shares of Common Stock (par value $0.001 per share) Underwriting AgreementUnderwriting Agreement • June 17th, 2020 • Celldex Therapeutics, Inc. • In vitro & in vivo diagnostic substances • New York
Celldex Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 13,377,926 shares of its common stock, par value $0.001 per share (the “Shares”). The 13,377,926 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 2,006,688 Shares pursuant to such option collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Cantor Fitzgerald & Co. (“Cantor”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representative” as used herein shall mean Cantor, as Underw
